FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV704620746US Express Mail Label Number

1

Date of Deposit)

	1 PTO-1 / 10-96		Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER PA/4-33291A								
		TRANSMITTAL LETTER TO 1	HE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
		DESIGNATED/ELECTED O										
		CONCERNING A FILING UN	•	10/565454								
IN	ΓER	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED								
PC	T/EI	P2004/008281	24 July 2003 (24.07.03)									
TITLE OF INVENTION												
	STABLE MODIFICATIONS OF TEGASEROD HYDROGEN MALEATE APPLICANT(S) FOR DO/EO/US											
	PFEFFER ET AL.											
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:												
1.	\boxtimes	This is a FIRST submission of items cond	cerning a filing under 35 U.S.C. 371.									
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.										
3.		This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).										
4.	\boxtimes	A proper Demand for International Prelim date.	ninary Examination was made by the 19	th month from the earliest claimed priority								
5.	\boxtimes	A copy of the International Application as	filed (35 U.S.C. 371(c)(2))									
		a. 🔲 is transmitted herewith (required only if not transmitted by the International Bureau).										
		 b. A has been transmitted by the Inter c. a is not required, as the application 										
6.		A translation of the International Applicat	ion into English (35 U.S.C. 371(c)(2)).	, ,								
7.	\boxtimes	Amendments to the claims of the Internal										
		a. are transmitted herewith (requiredb. have been transmitted by the Interest	d only if not transmitted by the Internatio	onal Bureau).								
			ne time limit for making such amendmen	its has NOT expired.								
		d. Maye not been made and will not										
8. 9.	X	A translation of the amendments to the cl An executed Declaration and Power of A	laims under PCT Article 19 (35 U.S.C. 3 Horney (original or copy) (35 U.S.C. 371	/1 (c)(3)). (c)(4)\ .								
		A translation of the annexes to the Intern										
		371(c)(5)).										
lter	ns 1	1. to 16. below concern document(s) or	information included.									
11.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.										
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
13.	\boxtimes	A FIRST preliminary amendment.										
		A SECOND or SUBSEQUENT preliminar	y amendment.									
14.	\boxtimes	An Application Data Sheet under 37 CFR 1.76.										
15.		A substitute specification.										
16.		A change of power of attorney and/or address letter.										
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.										
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).										
19.		A second copy of the English language tr	anslation of the International application	under 35 U.S.C. 154(d)(4).								
20.		Other items or information:										

	APPLICATION NO. (if known, see 37 CFR 1.5) PCT/EP2004/008281			_		ATTORNEY'S DOCKET NUMBER PA/4-33291A						
The following fe										CULATIO	NS PTO USE	
									ONLY			
21. 🛭 Basi	21. 🛛 Basic national fee											
22. Examination Fee												
	☐ If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)											
<u>. </u>				.,,,				·				
All other situations. \$200												
23. Search fee												
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international												
application to the USPTO as an International Searching Authority \$ ☑ If International Search Report was prepared and provided to the Office \$400												
All other situations												
TOTAL OF 21, 22 AND 23 =									\$	900		
			rawings filed	in paper over 100	sheets (
thereof.				e fee is \$250 for e				<u> </u>	r fracti	on		٠
Total Sheets	Extra	sheets		ach additional 50 old up to a whole n		n	F	RATE				
25 - 100 =		/50 =	(0		コ	X \$	250	\$		· · · · · · · · · · · · · · · · · · ·	
Surcharge of \$1	30 for fu	rnishina the	oath of decla	ration later than	□ 30				\$			
months from the earliest claimed priority date (37 CFR 1.492(e)).								Ψ				
CLAIMS NUMBE Total claims 15			- 20 =	NUMBER EX 0	TRA	×	RA \$	TE 50	\$		<u> </u>	
Independent cla		6	- 3 =	3		X		200	\$	600		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360								\$	4.500			
TOTAL OF ABOVE CALCULATIONS =									\$	1,500		_
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).									\$			
SUBTOTAL =									\$	1,500		\dashv
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).								\$				
		•						AL FEE =	\$	1,500		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied												
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + TOTAL FEES ENCLOSED =								LOSED =	\$	1,500		\dashv
TOTAL I LES ENCEOSED =									_	mount to	\$	
									be:	refunded		_
a. A check in the amount of \$ to cover the above fees is enclosed.										charged	\$	_
<u> </u>		-								or the abou	ro food A	
	Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,500 to cover the above fees. A duplicate copy of this form is enclosed.											
	c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										D	
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently:												
Peter J. Waibel												
Novartis Attorney for Applicants Corporate Intellectual Property Reg. No. 43,228												
One Health Plaza, Building 104 (862) 778-7951 East Hanover, NJ 07936-1080												
Lastria	HOVEL, IN	5 57 550- 100										

CALL, 1-800-222-1811 FOR PICKUR OR TRACKING OF ALL YOUR PACKAGE

